Ignite Creation Date:
2025-12-24 @ 6:41 PM
Ignite Modification Date:
2026-01-03 @ 10:21 PM
Study NCT ID:
NCT01951157
Status:
COMPLETED
Last Update Posted:
2019-09-24
First Post:
2013-09-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
Sponsor:
PharmaMar
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-09-11
Start Date Type:
ACTUAL
Primary Completion Date:
2016-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-11
Completion Date Type:
ACTUAL
First Submit Date:
2013-09-17
First Submit QC Date:
None
Study First Post Date:
2013-09-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-05-21
Results First Submit QC Date:
None
Results First Post Date:
2019-09-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-09-04
Last Update Post Date:
2019-09-24
Last Update Post Date Type:
ACTUAL